Accueil   Diary - News   All news Tollys appoints Amina Zinaï, MD, as head of clinical development

Tollys appoints Amina Zinaï, MD, as head of clinical development

 

Drawing on her expertise, Dr. Zinaï will be supporting Tollys in its
early clinical developments

 

 

Lyon, France, April 12, 2021 — Tollys, a biopharmaceutical company developing TL532, the first synthetic specific agonist of Toll-like receptor 3 (TLR3) cancer immunotherapy, today announces the appointment of Dr. Amina Zinaï as head of clinical development. Dr. Nasser Azli will remain in the role of chief medical officer.

 


“We are delighted to welcome Amina to our medical team,” said Vincent Charlon, CEO of Tollys. “Thanks to her expertise in clinical development and in drug candidate evaluation, she will be a real asset in Tollys’ crucial next steps as we prepare to launch initial clinical trials in 2022.”

 

 

Read the press release